Agios Pharmaceuticals, Inc. (AGIO)

Market Cap	2.52B
Revenue (ttm)	44.79M
Net Income (ttm)	-401.27M
Shares Out	58.31M
EPS (ttm)	-6.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	719,277
Open	42.86
Previous Close	43.18
Day's Range	42.26 - 43.72
52-Week Range	23.42 - 62.58
Beta	0.84
Analysts	Strong Buy
Price Target	59.33 (+37.05%)
Earnings Date	Oct 30, 2025

About AGIO

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patien...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 24, 2013
• Employees: 488
• Stock Exchange: NASDAQ
• Ticker Symbol: AGIO
• Website: https://www.agios.com

Analyst Summary

According to 4 analysts, the average rating for AGIO stock is "Strong Buy." The 12-month stock price target is $59.33, which is an increase of 37.05% from the latest price.

Price Target

$59.33

(37.05% upside)

Analyst Consensus: Strong Buy